DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim, Hyun | ko |
dc.contributor.author | Jang, Ju Hye | ko |
dc.contributor.author | Kim, Sun Chang | ko |
dc.contributor.author | Cho, Ju Hyun | ko |
dc.date.accessioned | 2020-01-14T07:20:12Z | - |
dc.date.available | 2020-01-14T07:20:12Z | - |
dc.date.created | 2020-01-14 | - |
dc.date.created | 2020-01-14 | - |
dc.date.created | 2020-01-14 | - |
dc.date.issued | 2020-01 | - |
dc.identifier.citation | EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, v.185 | - |
dc.identifier.issn | 0223-5234 | - |
dc.identifier.uri | http://hdl.handle.net/10203/271179 | - |
dc.description.abstract | The emergence of multidrug-resistant (MDR) Pseudomonas aeruginosa, coupled with shrinking antibiotic pipelines, has increased the demand for new antimicrobials with novel mechanisms of action. As the indiscriminate nature of broad-spectrum antimicrobial toxicity may have negative clinical consequences and increase the incidence of resistance, we have developed a P. aeruginosa-selective antimicrobial peptide capable of preferentially killing P. aeruginosa relative to benign microorganisms. A targeting peptide (PA2) that binds specifically to OprF porin on P. aeruginosa was identified by phage display peptide library screening, and a hybrid peptide was constructed by addition of the targeting peptide to GNU7, a potent antimicrobial peptide. The resulting hybrid peptide PA2-GNU7 exhibited potent antimicrobial activity against P. aeruginosa without causing host toxicity. Confocal laser scanning microscopy analysis and time-kill experiments demonstrated that PA2-GNU7 exhibited a high degree of specificity for P. aeruginosa, and rapidly and selectively killed P. aeruginosa cells in mixed cultures. In addition, in vivo treatment efficacy of PA2-GNU7 was significantly greater than that of conventional antibiotics in a mouse model of MDR P. aeruginosa infection. Taken together, the data suggest that PA2-GNU7 may be a promising template for further development as a novel anti-MDR P. aeruginosa therapeutic agent. (C) 2019 Elsevier Masson SAS. All rights reserved. | - |
dc.language | English | - |
dc.publisher | ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER | - |
dc.title | Development of a novel hybrid antimicrobial peptide for targeted killing of Pseudomonas aeruginosa | - |
dc.type | Article | - |
dc.identifier.wosid | 000503099900028 | - |
dc.identifier.scopusid | 2-s2.0-85074162623 | - |
dc.type.rims | ART | - |
dc.citation.volume | 185 | - |
dc.citation.publicationname | EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY | - |
dc.identifier.doi | 10.1016/j.ejmech.2019.111814 | - |
dc.contributor.localauthor | Kim, Sun Chang | - |
dc.contributor.nonIdAuthor | Kim, Hyun | - |
dc.contributor.nonIdAuthor | Jang, Ju Hye | - |
dc.contributor.nonIdAuthor | Cho, Ju Hyun | - |
dc.description.isOpenAccess | N | - |
dc.type.journalArticle | Article | - |
dc.subject.keywordAuthor | Antimicrobial peptide | - |
dc.subject.keywordAuthor | Hybrid peptide | - |
dc.subject.keywordAuthor | Multidrug-resistant Pseudomonas aeruginosa | - |
dc.subject.keywordAuthor | OprF | - |
dc.subject.keywordAuthor | Selective antimicrobial activity | - |
dc.subject.keywordPlus | MEMBRANE PROTEIN OPRF | - |
dc.subject.keywordPlus | HOST-DEFENSE PEPTIDES | - |
dc.subject.keywordPlus | ANTIBIOTICS | - |
dc.subject.keywordPlus | PATHOGENESIS | - |
dc.subject.keywordPlus | ENHANCEMENT | - |
dc.subject.keywordPlus | SELECTIVITY | - |
dc.subject.keywordPlus | INFECTIONS | - |
dc.subject.keywordPlus | RESISTANCE | - |
dc.subject.keywordPlus | BACTERIA | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.